Clinical Research Directory
Browse clinical research sites, groups, and studies.
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Sponsor: University of Calgary
Summary
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
Official title: The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
8805
Start Date
2026-06-04
Completion Date
2030-12
Last Updated
2026-07-27
Healthy Volunteers
No
Interventions
Aspirin
75-100 mg taken once daily by mouth.
Low-molecular-weight heparin
Low-molecular-weight heparin injections daily as prescribed by the treating physician.
Locations (12)
Association Hospitalière De Bruxelles Et De Schaerbeek - Centre Hospitalier Universitaire Brugmann
Brussels, Belgium
Foothills Medical Centre
Calgary, Alberta, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Hvidovre Hospital
Hvidovre, Capital Region, Denmark
CHU de Nancy
Nancy, France
APHP - Hôpital Port Royal
Paris, France
CHU de Saint-Etienne
Saint-Etienne, France
CHU de Toulouse
Toulouse, France
Rotunda Hospital, RCSI Department of Obstetrics and Gynaecology
Dublin, Ireland
UCD Centre for Human Reproduction, The Coombe Hospital
Dublin, Ireland
Amsterdam UMC
Amsterdam, Netherlands
Medical University of Warsaw
Warsaw, Poland